Given the increasingly important role of immunotherapy agents in the treatment of haematological cancers, Diag2Tec developed services to evaluate the efficacy, mechanisms of action, and resistance of immune-based therapies in our hematologic malignancies models (cell lines, primary samples and plasma cell differentiation model).
Given the increasingly important role of immunotherapy agents in the treatment of haematological cancers, Diag2Tec developed services to evaluate the efficacy, mechanisms of action, and resistance of immune-based therapies in our hematologic malignancies models (cell lines, primary samples and plasma cell differentiation model).
Clinically Relevant Models
For these services, Diag2Tec selects the best models according to the needs of the preclinical studies. Diag2Tec leverages a comprehensive portfolio of models, including validated hematologic cancer cell lines, unique proprietary panel of multiple myeloma cell lines, primary samples from patients with hematologic malignancies (Multiple Myeloma, Non-Hodgkin Lymphoma, Acute and Chronic Leukemia…), and our normal plasma cell differentiation model. These systems are enriched with integrated clinical, biological and genomic data ensuring strong translational relevance (age, gender, subtypes, gene expression profile, mutations, FISH, epigenetic data, treatment and response…).
Assays and Functional Readouts
We provide advanced assays to assess the direct and immune-mediated cytotoxicity (ADCC, ADCP, CDC, Bipsecific) for monoclonal antibodies, bispecifics, trispecifics, and antibody-drug conjugates (ADCs):
- Co-culture systems with PBMCs or specific immune cells from patients or healthy donors (NK, T cells, monocytes)
- Co-culture systems of primary samples within their microenvironment when sufficient to assess immune therapy effects.
- Single-agent and combination treatment strategies
- Viability and targeted depletion of tumor and non-tumor cells via multiparametric flow cytometry
- Immunophenotyping of immune cells (including activation or exhaustion markers) via multiparametric flow cytometry
- Cytokine release analysis from culture supernatants
- Customized assays on request
Deliverables
High-quality, decision-ready data packages including comprehensive reports, as well as raw and processed datasets to support preclinical and translational development.